Vaccines based on mRNA played a significant role during COVID pandemic .

A Cancer vaccine based on mRNA is showing lot of promise in a type of skin cancer called melanoma.

Results presented at the ASCO meeting in Chicago show better survival outcome compared to the current standard immunotherapy.

Confirmatory trials are in progress to provide further evidence for this personalised vaccine.

References

Guardian: ‘Extremely impressive’: melanoma jab trial results excite doctors. Andrew Gregory. Health editor. Mon 3 Jun 2024 22.00 BST

ASCO Abstract. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.

ASCO Trials in Progress. INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.